Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

(2020) Bruno Bockorny et al.   NATURE MEDICINE

Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

(2019) K M Heinhuis et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Autophagy inhibition enhances PD-L1 expression in gastric cancer

(2019) Xiaojuan Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Sigma-1 receptor ablation impairs autophagosome clearance

(2019) Huan Yang et al.   Autophagy

A Hypoxia‐Responsive Albumin‐Based Nanosystem for Deep Tumor Penetration and Excellent Therapeutic Efficacy

(2019) Guangbao Yang et al.   ADVANCED MATERIALS

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

(2019) Chin-King Looi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis

(2019) Quisette P Janssen et al.   JNCI-Journal of the National Cancer Institute

Cancer nanomedicine for combination cancer immunotherapy

(2019) Jutaek Nam et al.   Nature Reviews Materials

Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences

(2019) Mara Cirone et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges

(2019) Feng Yang et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Checkpoint inhibitors in pancreatic cancer

(2019) Andreas Henriksen et al.   CANCER TREATMENT REVIEWS

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches

(2019) Michael Orth et al.   Radiation Oncology

Irinotecan: 25 years of cancer treatment

(2019) Christian Bailly   PHARMACOLOGICAL RESEARCH

Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer

(2018) Huan Meng et al.   ADVANCED DRUG DELIVERY REVIEWS

Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy

(2018) Flavia Radogna et al.   BIOCHEMICAL PHARMACOLOGY

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

(2018) Zishuo I. Hu et al.   CLINICAL CANCER RESEARCH

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

(2018) Femke M. de Man et al.   CLINICAL PHARMACOKINETICS

PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay

(2018) Xiaolong Liang et al.   Diagnostic Pathology

Therapeutic developments in pancreatic cancer: current and future perspectives

(2018) John P. Neoptolemos et al.   Nature Reviews Gastroenterology & Hepatology

Structural and photodynamic properties of the anti-cancer drug irinotecan in aqueous solutions of different pHs

(2018) Maria Rosaria di Nunzio et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

(2018) Toshiki Iwai et al.   Oncotarget

Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer

(2018) Sayeda Yasmin-Karim et al.   Frontiers in Immunology

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

(2018) Derya Kabacaoglu et al.   Frontiers in Immunology

Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy

(2018) Sara Musetti et al.   ACS Nano

Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer

(2018) Xiangsheng Liu et al.   ACS Nano

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer

(2017) Xiangsheng Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors

(2017) Richard A. Skelton et al.   JOURNAL OF SURGICAL ONCOLOGY

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

(2017) Jodi A McKenzie et al.   JNCI-Journal of the National Cancer Institute

PD-L1 Expression in Pancreatic Cancer

(2017) Lei Zheng   JNCI-Journal of the National Cancer Institute

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Effect of lysosomotropic molecules on cellular homeostasis

(2017) Omer F. Kuzu et al.   PHARMACOLOGICAL RESEARCH

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

(2017) Xiaohui Wang et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

(2017) Jodi A McKenzie et al.   JNCI-Journal of the National Cancer Institute

PD-L1 Expression in Pancreatic Cancer

(2017) Lei Zheng   JNCI-Journal of the National Cancer Institute

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Designing nanomedicine for immuno-oncology

(2017) Wen Jiang et al.   Nature Biomedical Engineering

Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer

(2016) Xiangsheng Liu et al.   ACS Nano

Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy

(2016) Xiao Zhao et al.   BIOMATERIALS

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Real-time self-tracking of an anticancer small molecule nanodrug based on colorful fluorescence variations

(2016) Siteng Wang et al.   RSC Advances

Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes

(2015) Daniel Yuan Qiang Wong et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The Role of Endoplasmic Reticulum Stress in Human Pathology

(2015) Scott A. Oakes et al.   Annual Review of Pathology-Mechanisms of Disease

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Immunogenic cell death

(2015) Abhishek D. Garg et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

(2015) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

ENDOPLASMIC RETICULUM STRESS IN SEPSIS

(2015) Mohammad Moshahid Khan et al.   SHOCK

Autophagosome–lysosome fusion is independent of V-ATPase-mediated acidification

(2015) Caroline Mauvezin et al.   Nature Communications

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

(2015) Jonathan Pol et al.   OncoImmunology

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

(2014) M. Aglietta et al.   ANNALS OF ONCOLOGY

ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses

(2014) Abhishek D. Garg et al.   PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

(2014) E. R. Lutz et al.   Cancer Immunology Research

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Two-Wave Nanotherapy To Target the Stroma and Optimize Gemcitabine Delivery To a Human Pancreatic Cancer Model in Mice

(2013) Huan Meng et al.   ACS Nano

The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells

(2013) Stanislav John et al.   Anti-Cancer Agents in Medicinal Chemistry

ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death

(2013) Abhishek D. Garg et al.   Autophagy

Crosstalk between ER stress and immunogenic cell death

(2013) Oliver Kepp et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation

(2013) Hongyan Wei et al.   Asian Journal of Pharmaceutical Sciences

Multifunctional Mesoporous Silica Nanoparticles for Cancer-Targeted and Controlled Drug Delivery

(2012) Quan Zhang et al.   ADVANCED FUNCTIONAL MATERIALS

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Chronic Autophagy Is a Cellular Adaptation to Tumor Acidic pH Microenvironments

(2012) Jonathan W. Wojtkowiak et al.   CANCER RESEARCH

PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress

(2012) T Verfaillie et al.   CELL DEATH AND DIFFERENTIATION

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

(2012) Abhishek D Garg et al.   EMBO JOURNAL

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer

(2012) Anastasios Dimou et al.   Therapeutic Advances in Medical Oncology

Endoplasmic Reticulum Stress-induced Apoptosis inLeishmaniathrough Ca2+-dependent and Caspase-independent Mechanism

(2011) Subhankar Dolai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host

(2010) W. W. Tseng et al.   CLINICAL CANCER RESEARCH

Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma

(2010) Liancai Wang et al.   WORLD JOURNAL OF SURGERY

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

(2008) J A Burger et al.   LEUKEMIA

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

(2008) Paul Tardi et al.   LEUKEMIA RESEARCH